{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:32:44Z","timestamp":1789227164968,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jgo.2026.102933","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T04:30:12Z","timestamp":1772598612000},"page":"102933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Barriers and facilitators of deprescribing for older adults with cancer and polypharmacy"],"prefix":"10.1016","volume":"17","author":[{"given":"Kofi Gyasi","family":"Agyei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arul","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally A.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Juba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Mohile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Ramsdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2026.102933_bb0005","series-title":"Geriatric oncology","first-page":"1","article-title":"Comorbidity in aging and cancer","author":"Ramsdale","year":"2019"},{"issue":"7","key":"10.1016\/j.jgo.2026.102933_bb0010","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/cncr.34642","article-title":"Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer","volume":"129","author":"Mohamed","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2026.102933_bb0015","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"issue":"6","key":"10.1016\/j.jgo.2026.102933_bb0020","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jgo.2021.01.009","article-title":"Research priorities to address polypharmacy in older adults with cancer","volume":"12","author":"Nightingale","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2026.102933_bb0025","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1634\/theoncologist.2019-0406","article-title":"Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis","volume":"25","author":"Mohamed","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.jgo.2026.102933_bb0030","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00432-015-2108-x","article-title":"Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer","volume":"142","author":"Park","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2026.102933_bb0035","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101096","article-title":"Barriers and facilitators to deprescribing in primary care: a systematic review","volume":"4","author":"Doherty","year":"2020","journal-title":"BJGP Open"},{"issue":"1","key":"10.1016\/j.jgo.2026.102933_bb0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.jgo.2026.102933_bb0045","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","article-title":"Reducing inappropriate polypharmacy: the process of deprescribing","volume":"175","author":"Scott","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.jgo.2026.102933_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101531","article-title":"Medication assessment in older adults with cancer \u2013 current practices in clinical pharmacy","volume":"14","author":"Walsh","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2026.102933_bb0055","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/bcp.12732","article-title":"A systematic review of the emerging de fi nition of \u2018deprescribing\u2019 with network analysis: implications for future research and clinical practice","volume":"80","author":"Reeve","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jgo.2026.102933_bb0060","first-page":"2933","article-title":"Deprescribing in palliative patients with cancer: a concise review of tools and guidelines","volume":"30","author":"van Merendonk","year":"2022","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2026.102933_bb0065","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/joim.13599","article-title":"Implementation considerations of deprescribing interventions: a scoping review","volume":"295","author":"Wang","year":"2024","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.jgo.2026.102933_bb0070","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/jgs.19305","article-title":"Communication as a key component of deprescribing: conceptual framework and review of the literature","volume":"73","author":"Fried","year":"2025","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.jgo.2026.102933_bb0075","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ijpp\/riad025","article-title":"A systematic review of randomised-controlled trials on deprescribing outcomes in older adults with polypharmacy","volume":"31","author":"Omuya","year":"2023","journal-title":"Int J Pharm Pract"},{"issue":"12","key":"10.1016\/j.jgo.2026.102933_bb0080","first-page":"4105","article-title":"Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study","volume":"26","author":"Whitman","year":"2018","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.jgo.2026.102933_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101472","article-title":"Potentially inappropriate medication use based on two deprescribing criteria and related factors in patients with terminal cancer: a cross-sectional study","volume":"14","author":"Kim","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2026.102933_bb0090","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/ijpp\/riad001","article-title":"Barriers and facilitators of implementing proactive deprescribing within primary care: a systematic review","volume":"31","author":"Okeowo","year":"2023","journal-title":"Int J Pharm Pract"},{"issue":"1","key":"10.1016\/j.jgo.2026.102933_bb0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/0269216318801124","article-title":"Barriers and enablers to deprescribing in people with a life-limiting disease: a systematic review","volume":"33","author":"Paque","year":"2019","journal-title":"Palliat Med"},{"key":"10.1016\/j.jgo.2026.102933_bb0100","article-title":"The role of U.S. pharmacists in deprescribing: recommendations based on a systematic literature review of qualitative studies","volume":"19","author":"Cernasev","year":"2025","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"4","key":"10.1016\/j.jgo.2026.102933_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101450","article-title":"Impact of pharmaceutical care interventions on multidisciplinary care of older patients with cancer: a systematic review","volume":"14","author":"Herledan","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2026.102933_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101687","article-title":"Decreasing polypharmacy in older adults with cancer: a pilot cluster-randomized trial protocol","volume":"15","author":"Ramsdale","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2026.102933_bb0115","series-title":"Basic and advanced focus groups","author":"Morgan","year":"2019"},{"key":"10.1016\/j.jgo.2026.102933_bb0120","series-title":"Naturalistic inquiry","author":"Lincoln","year":"1985"},{"issue":"12","key":"10.1016\/j.jgo.2026.102933_bb0125","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jamainternmed.2018.4720","article-title":"Assessment of attitudes toward deprescribing in older Medicare beneficiaries in the United States","volume":"178","author":"Reeve","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.jgo.2026.102933_bb0130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13690-025-01700-6","article-title":"Association between older adults\u2019 socioeconomic status and their healthcare experiences, preferences, and attitudes towards deprescribing: a cross-sectional study in 14 countries","volume":"83","author":"Luthold","year":"2025","journal-title":"Arch Public Health"},{"issue":"12","key":"10.1016\/j.jgo.2026.102933_bb0135","article-title":"Emotional barriers and facilitators of deprescribing for older adults with cancer and polypharmacy: a qualitative study","volume":"31","author":"Ramsdale","year":"2023","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2026.102933_bb0140","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bcp.14947","article-title":"Community-based pharmacists\u2019 role in deprescribing: a systematic review","volume":"88","author":"Buzancic","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.jgo.2026.102933_bb0145","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4140\/TCP.n.2023.506","article-title":"The effect of pharmacist-initiated deprescribing interventions in older people: a narrative review of randomized controlled trials","volume":"38","author":"Nguyen","year":"2023","journal-title":"Sr Care Pharm"},{"key":"10.1016\/j.jgo.2026.102933_bb0150","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.2147\/PPA.S323846","article-title":"Exploring patients\u2019 attitudes toward deprescribing and their perception of pharmacist involvement in a European country: a cross-sectional study","volume":"15","author":"Buzancic","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"18","key":"10.1016\/j.jgo.2026.102933_bb0155","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/ajhp\/zxaf150","article-title":"ASHP national survey of pharmacy practice in hospital settings: clinical services and Workforce-2024","volume":"82","author":"Pedersen","year":"2025","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.jgo.2026.102933_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyac053","article-title":"Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment","author":"Ramsdale","year":"2022","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.jgo.2026.102933_bb0165","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","author":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.jgo.2026.102933_bb0170","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s41999-023-00777-y","article-title":"STOPP\/START criteria for potentially inappropriate prescribing in older people: version 3","volume":"14","author":"O\u2019Mahony","year":"2023","journal-title":"Eur Geriatr Med"},{"key":"10.1016\/j.jgo.2026.102933_bb0175","doi-asserted-by":"crossref","DOI":"10.1177\/1609406919874596","article-title":"Using zoom videoconferencing for qualitative data collection: perceptions and experiences of researchers and participants","volume":"18","author":"Archibald","year":"2019","journal-title":"Int J Qual Methods"},{"issue":"5","key":"10.1016\/j.jgo.2026.102933_bb0180","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.amjsurg.2020.10.009","article-title":"Implementation of virtual focus groups for qualitative data collection in a global pandemic","volume":"221","author":"Dos Santos Marques","year":"2021","journal-title":"Am J Surg"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826000871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406826000871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:03:12Z","timestamp":1777622592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406826000871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1879406826000871"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102933","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers and facilitators of deprescribing for older adults with cancer and polypharmacy","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102933"}}